Sight Sciences Inc
$ 4.45
-3.26%
05 Jun - close price
- Market Cap 242,124,000 USD
- Current Price $ 4.45
- High / Low $ 4.58 / 4.42
- Stock P/E N/A
- Book Value 1.20
- EPS -0.70
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.57 %
- 52 Week High 9.24
- 52 Week Low 3.11
About
Sight Sciences Inc. (SGHT) is a pioneering medical technology firm focused on transforming the treatment of ocular diseases, with a primary emphasis on glaucoma management through innovative surgical and non-surgical approaches. The company is well-equipped with a robust product lineup and a comprehensive intellectual property portfolio, allowing it to capitalize on the escalating demand for minimally invasive ophthalmic therapies. With ongoing advancements in its distribution network and a commitment to advancing eye care technology, Sight Sciences offers a compelling opportunity for institutional investors aiming to participate in the dynamic healthcare sector.
Analyst Target Price
$8.54
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-04 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-05 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-07 | 2023-08-03 |
| Reported EPS | -0.24 | -0.08 | -0.16 | -0.23 | -0.28 | -0.23 | -0.22 | -0.25 | -0.33 | -0.22 | -0.27 | -0.3 |
| Estimated EPS | -0.1692 | -0.1529 | -0.26 | -0.26 | -0.28 | -0.176 | -0.21 | -0.3 | -0.28 | -0.32 | -0.32 | -0.34 |
| Surprise | -0.0708 | 0.0729 | 0.1 | 0.03 | 0 | -0.054 | -0.01 | 0.05 | -0.05 | 0.1 | 0.05 | 0.04 |
| Surprise Percentage | -41.844% | 47.6782% | 38.4615% | 11.5385% | 0% | -30.6818% | -4.7619% | 16.6667% | -17.8571% | 31.25% | 15.625% | 11.7647% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SGHT
2026-06-05 20:09:59
Sight Sciences, Inc. (NASDAQ: SGHT) has reported the results of its annual stockholder meeting held on June 4, 2026. Shareholders elected Gerhard Burbach and Staffan Encrantz as Class II directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Approximately 76.2% of outstanding shares were represented at the meeting, with no other matters brought to a vote.
2026-06-05 20:09:59
Sight Sciences (SGHT) director Tamara Fountain was granted 28,261 Restricted Stock Units (RSUs) on June 4, 2026, as part of the company's Non-Employee Director Compensation Program. This award represents approximately $130,000 in common stock value based on the closing price that day. The RSUs are set to vest on the earlier of June 4, 2027, or the company's 2027 annual stockholders' meeting, contingent on her continued board service, bringing her total holdings to 109,650 shares and units.
2026-06-05 20:09:59
Sight Sciences (NASDAQ: SGHT) director Catherine Mazzacco was granted 28,261 Restricted Stock Units (RSUs) as board compensation on June 4, 2026. This equity award is valued at approximately $130,000 and eschews a cash cost, vesting on the earlier of June 4, 2027, or the company's 2027 annual meeting, dependent on her continued service. Following this transaction, Mazzacco directly holds 69,276 shares and RSUs, along with 37,492 shares held indirectly through an irrevocable trust.
2026-06-01 09:10:27
Sight Sciences, Inc. (SGHT) reported a Q1 loss of $0.16 per share, outperforming the Zacks Consensus Estimate of a $0.19 loss and an improvement from the $0.28 loss per share a year ago. The company also surpassed revenue estimates, posting $19.7 million against an expected $18.57 million. Despite beating earnings and revenue expectations, Sight Sciences' shares have declined about 45.4% year-to-date, with the stock currently holding a Zacks Rank #3 (Hold).
2026-05-29 21:39:19
Sight Sciences Inc (SGHT) experienced muted trading on Nasdaq as investors await Q2 earnings and regulatory updates. The eye-care company specializes in minimally invasive devices for glaucoma and dry eye treatments. Valuation focuses on growth metrics given its stage as a smaller-cap healthcare technology firm, with emphasis on revenue expansion and margin trends.
2026-05-28 15:10:29
Citigroup has maintained a Neutral rating on Sight Sciences (SGHT), increasing its price target to $5.15 from $4.35. Despite this, GuruFocus indicates that SGHT is currently overvalued by 13.3% relative to its GF Value™ of $4.46, suggesting caution for investors. The company's GF Score™ of 73 reflects strong growth potential but highlights challenges in profitability, while recent insider activity shows sales but no purchases of stock.
